Press Releases
Tovorafenib FDA Approval for low-grade glioma
PNOC Foundation announces FDA approval of tovorafenib (day101) in partnership with pnoc scientific consortium and day one biopharmaceuticals
Journal of Clinical Oncology PNOC001: Phase II Study of Everolimus For Recurrent or Progressive Low-Grade Gliomas in Children
The PNOC001 phase II single-arm trial sought to estimate progression-free survival (PFS) associated with everolimus therapy for progressive/recurrent pediatric low-grade glioma (pLGG) on the basis of phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway activation as measured by phosphorylated-ribosomal protein S6 and to identify prognostic and predictive biomarkers.
Neoplasia Journal Machine Learning Identifies Subgroups of Pediatric Low-grade Gliomas that Correlate with Key Molecular Markers
Despite advancements in molecular and histopathologic characterization of pediatric low-grade gliomas (pLGGs), there remains significant phenotypic heterogeneity among tumors with similar categorizations.